Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 8/20 | 0.44 |
| ▸ | CDK2 | P24941 | 6/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | PRKACG | P22612 | 1/20 | 0.32 |
| ▸ | PRKACB | P22694 | 1/20 | 0.32 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15887583 | 0.82 | CDK1 (0.47) | CDK1CDK2CCNE1CCNB1SLC29A1 | |
| SCHEMBL12522765 | 0.80 | CDK1 (0.50) | CDK1CDK2CCNE1CCNB1ADORA2A | |
| SCHEMBL21562148 | 0.79 | CDK1 (0.49) | CDK1CDK2CCNE1CCNB1SLC29A1 | |
| SCHEMBL12522769 | 0.76 | CDK1 (0.53) | CDK1CDK2CCNE1CCNB1ADORA2A | |
| SCHEMBL14087936 | 0.76 | CDK1 (0.47) | CDK1CDK2CCNE1CCNB1SLC29A1 | |
| SCHEMBL14619498 | 0.74 | CDK2 (0.45) | CDK1CDK2CCNE1CCNB1ADORA2A | |
| SCHEMBL3209666 | 0.73 | CDK1 (0.60) | CDK1CDK2CCNE1CCNB1CCNA2 | |
| SCHEMBL20857246 | 0.73 | CDK1 (0.49) | CDK1CDK2CCNE1CCNB1ADORA2A | |
| SCHEMBL22915720 | 0.71 | CDK1 (0.48) | CDK1CDK2CCNE1CCNB1ADORA2A | |
| SCHEMBL24021902 | 0.70 | CDK1 (0.53) | CDK1CDK2CCNE1CCNB1SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718855-B2 | Nucleosides and oligonucleotides for studies on reversal of cytotoxic and mutagenic damage of DNA and as diagnostics tools | CHEMGENES CORPORATION (US) | 2017-08-01 | — | — | US | disclosed |
| US-20140350234-A1 | Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools | CHEMGENES CORPORATION (US) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350234-A1 | Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools | UNG, OGG1, ADAR | CDK1 2111/4885CDK2 2817/4885CCNE1 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.